MX392677B - Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes. - Google Patents

Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.

Info

Publication number
MX392677B
MX392677B MX2018003023A MX2018003023A MX392677B MX 392677 B MX392677 B MX 392677B MX 2018003023 A MX2018003023 A MX 2018003023A MX 2018003023 A MX2018003023 A MX 2018003023A MX 392677 B MX392677 B MX 392677B
Authority
MX
Mexico
Prior art keywords
patients
compositions
treatment
neurodegenerative disorders
particular population
Prior art date
Application number
MX2018003023A
Other languages
English (en)
Other versions
MX2018003023A (es
Inventor
Aidan Power
Jeremy Yu
John Hey
Martin Tolar
Petr Kocis
Susan Abushakra
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX392677(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of MX2018003023A publication Critical patent/MX2018003023A/es
Publication of MX392677B publication Critical patent/MX392677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aquí se describen métodos para tratar, mejorar y/o prevenir la enfermedad de Alzheimer en una población de pacientes específica utilizando tramiprosato, ácido valil-3-amino-1-propansulfónico o una sal farmacéuticamente aceptable del mismo basado en una combinación de estado APOE4 y gravedad de la enfermedad.
MX2018003023A 2015-09-10 2016-09-09 Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes. MX392677B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (2)

Publication Number Publication Date
MX2018003023A MX2018003023A (es) 2018-06-06
MX392677B true MX392677B (es) 2025-03-24

Family

ID=58240195

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003023A MX392677B (es) 2015-09-10 2016-09-09 Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
MX2022003128A MX2022003128A (es) 2015-09-10 2018-03-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003128A MX2022003128A (es) 2015-09-10 2018-03-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Country Status (21)

Country Link
US (3) US11191742B2 (es)
EP (2) EP3347002B1 (es)
JP (4) JP6789579B2 (es)
KR (2) KR102547164B1 (es)
CN (3) CN116712422A (es)
AU (1) AU2016319107B2 (es)
CA (1) CA2997376C (es)
DK (1) DK3347002T3 (es)
ES (1) ES2952727T3 (es)
FI (1) FI3347002T3 (es)
HR (1) HRP20230809T1 (es)
HU (1) HUE062511T2 (es)
LT (1) LT3347002T (es)
MD (1) MD3347002T2 (es)
MX (2) MX392677B (es)
PL (1) PL3347002T3 (es)
PT (1) PT3347002T (es)
RS (1) RS64481B1 (es)
SI (1) SI3347002T1 (es)
SM (1) SMT202300250T1 (es)
WO (1) WO2017044840A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
SMT202300250T1 (it) * 2015-09-10 2023-09-06 Alzheon Inc Trattamento della malattia di alzheimer in una particolare popolazione di pazienti
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
PL3829563T3 (pl) * 2018-08-01 2025-04-07 Alzheon, Inc. Kwas 3-sulfopropanowy do leczenia zaburzeń neurodegeneracyjnych
CA3108182A1 (en) * 2018-08-01 2020-02-06 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
UA129160C2 (uk) * 2019-06-17 2025-01-29 Алзхеон, Інк. Спосіб лікування хвороби альцгеймера
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
KR20240116529A (ko) * 2021-12-09 2024-07-29 알제온, 인크. 알츠하이머병 치료에 사용하기 위한 alz-801
JP2025504199A (ja) * 2022-02-07 2025-02-06 アルツェオン・インコーポレーテッド Ｃｏｖｉｄ－１９関連神経症状の治療に使用するためのａｌｚ－８０１

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP0625212B1 (en) 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
EP1890685A2 (en) * 2005-04-12 2008-02-27 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
CA2830727C (en) 2006-10-12 2016-11-29 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
CA2808630A1 (en) * 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2994160B1 (en) 2013-05-06 2019-07-03 Baxalta Incorporated Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2015214058B2 (en) * 2014-02-08 2020-07-09 Genentech, Inc. Methods of treating Alzheimer's Disease
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
SMT202300250T1 (it) * 2015-09-10 2023-09-06 Alzheon Inc Trattamento della malattia di alzheimer in una particolare popolazione di pazienti

Also Published As

Publication number Publication date
JP6789579B2 (ja) 2020-11-25
LT3347002T (lt) 2023-09-11
EP4275750A2 (en) 2023-11-15
ES2952727T3 (es) 2023-11-03
JP2022145949A (ja) 2022-10-04
EP3347002A1 (en) 2018-07-18
EP3347002A4 (en) 2019-04-24
KR102412997B1 (ko) 2022-06-23
CN108289870A (zh) 2018-07-17
KR102547164B1 (ko) 2023-06-22
PL3347002T3 (pl) 2023-11-13
HK1257874A1 (en) 2019-11-01
CA2997376A1 (en) 2017-03-16
JP7128536B2 (ja) 2022-08-31
SMT202300250T1 (it) 2023-09-06
SI3347002T1 (sl) 2023-12-29
MX2018003023A (es) 2018-06-06
MD3347002T2 (ro) 2023-10-31
US20230414541A1 (en) 2023-12-28
US11191742B2 (en) 2021-12-07
JP2025065545A (ja) 2025-04-17
JP2020200352A (ja) 2020-12-17
JP2018526407A (ja) 2018-09-13
RS64481B1 (sr) 2023-09-29
MX2022003128A (es) 2022-08-02
EP4275750A3 (en) 2024-01-17
CN116712422A (zh) 2023-09-08
KR20220042480A (ko) 2022-04-05
FI3347002T3 (fi) 2023-08-10
EP3347002B1 (en) 2023-06-07
CA2997376C (en) 2024-05-14
CN116712423A (zh) 2023-09-08
AU2016319107B2 (en) 2021-02-25
HRP20230809T1 (hr) 2023-10-27
DK3347002T3 (da) 2023-08-14
KR20180051561A (ko) 2018-05-16
US20220096406A1 (en) 2022-03-31
AU2016319107A1 (en) 2018-03-22
WO2017044840A1 (en) 2017-03-16
PT3347002T (pt) 2023-07-27
HUE062511T2 (hu) 2023-11-28

Similar Documents

Publication Publication Date Title
MX392677B (es) Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
MX2024010140A (es) Nuevos metodos.
MX387115B (es) Métodos para tratar la influenza.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
MX383499B (es) Agentes terapeuticos para enfermedades neurodegenerativas
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
MX381283B (es) Tratamiento de pénfigo.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
HK1253734A1 (zh) 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
WO2015143447A3 (en) Methods for treating neurological disorders
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2021005875A (es) Composiciones y métodos para el tratamiento de trastornos neurodegenerativos, miodegenerativos y de almacenamiento lisosómico.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain